Abk�rzung zur Hauptnavigation Abk�rzung zu den Newsmeldungen Abk�rzung zu den Topstories  
  Barrierefreiheit    Kontakt MedUni Wien    Intranet    MedUni Wien - Shop    Universitätsbibliothek    Universitätsklinikum AKH Wien  
 
ccc_logo_en.gif
 
AKH Wien
 
 
Hauptnavigation
  • Home
  • Über das CCC
    • Allgemeines
    • Leitung der Organisationseinheit
    • CCC-Office Team
    • Kliniken und Partner
    • Qualitätsmanagement
    • Kontakt
  • PatientInnen
    • Covid-19
    • Allgemeines
    • Cancer School
    • Terminvereinbarung
    • Pflegeambulanz
    • PatientInnenvertretung
    • Links
  • Klinischer Bereich
    • Allgemeines
    • CCC Tumorboards
  • Wissenschaft & Forschung
    • Young CCC
    • CCC-ExpertInnenvideos
    • CCC Forschungscluster
    • CCC Units
    • CCC Platforms
    • Translationale Forschung
    • CCC Best Paper Award
    • CCC-TRIO Symposium
    • Kontakt/Links
  • Lehre
    • CCC Cancer School
    • CCC Cancer Update
    • Vienna International Summer School on Clinical and Experimental Oncology - VSSO
    • Interdisziplinäre onkologische Ausbildung
    • Klinisch-Praktisches Jahr (KPJ)
    • PhD Programme
    • Postgraduelle Fort- und Weiterbildung
    • Information/Contact
 
 
Subnavigation
    Inhaltsbereich


    Zurück zur Übersicht
    Nature medicine. 2015 Aug 7. pii: nm.3915. doi: 10.1038/nm.3915
    Toward understanding and exploiting tumor heterogeneity.
    Alizadeh AA1,  Aranda V2,  Bardelli A3,  Blanpain C4,  Bock C5,  Borowski C6,  Caldas C7,  Califano A8,  Doherty M9,  Elsner M10,  Esteller M11,  Fitzgerald R12,  Korbel JO13,  Lichter P14,  Mason CE15,  Navin N16,  Pe'er D17,  Polyak K18,  Roberts CW19,  Siu L20,  Snyder A21,  Stower H22,  Swanton C23,  Verhaak RG24,  Zenklusen JC25,  Zuber J26,  Zucman-Rossi J27
    Author information
    11] Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA. [2] Division of Hematology, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA. [3] Cancer Institute, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.
    2Nature Medicine, New York, New York, USA.
    31] Department of Oncology, University of Torino, Candiolo, Torino, Italy. [2] Candiolo Cancer Institute-Fondazione del Piemonte per l'Oncologia (FPO), IRCCS, Candiolo, Torino, Italy.
    4Université Libre de Bruxelles (ULB), Brussels, Belgium.
    51] CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria. [2] Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.
    6Nature Medicine, New York, New York, USA.
    7Department of Oncology, University of Cambridge, Cambridge, UK.
    81] Department of Systems Biology, Columbia University, New York, New York, USA. [2] Department of Biochemistry and Molecular Biophysics, Columbia University, New York, New York, USA. [3] Department of Biomedical Informatics, Columbia University, New York, New York, USA.
    9Genentech Inc., South San Francisco, California, USA.
    10Nature Biotechnology, New York, New York, USA.
    11Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, Barcelona, Catalonia, Spain.
    12MRC Cancer Unit, Hutchison-MRC Research Centre, University of Cambridge, Cambridge, UK.
    13Genome Biology Unit, European Molecular Biology Laboratory, Heidelberg, Germany.
    14German Cancer Research Center, DKFZ, Heidelberg, Germany.
    15Weill Cornell Medical College, New York, New York, USA.
    161] Department of Genetics, MD Anderson Cancer Center, Houston, Texas, USA. [2] Department of Bioinformatics and Computational Biology, MD Anderson Cancer Center, Houston, Texas, USA.
    171] Department of Systems Biology, Columbia University, New York, New York, USA. [2] Department of Biological Sciences, Columbia University, New York, New York, USA.
    18Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
    19Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
    20Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
    21Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
    22Nature Medicine, New York, New York, USA.
    231] University College London Cancer Institute, London, UK. [2] University College London Hospitals NHS Foundation Trust, London, UK. [3] The Francis Crick Institute, London, UK.
    241] Department of Bioinformatics and Computational Biology, MD Anderson Cancer Center, Houston, Texas, USA. [2] Department of Genomic Medicine, MD Anderson Cancer Center, Houston, Texas, USA.
    25The Cancer Genome Atlas, Center for Cancer Genomics, National Cancer Institute, Bethesda, Maryland, USA.
    26Research Institute of Molecular Pathology (IMP), Vienna Biocenter (VBC), Vienna, Austria.
    27Inserm, UMR-1162, Génomique fonctionnelle des tumeurs solides, Institut Universitaire d'Hématologie (IUH), Paris, France.
    Abstract

    The extent of tumor heterogeneity is an emerging theme that researchers are only beginning to understand. How genetic and epigenetic heterogeneity affects tumor evolution and clinical progression is unknown. The precise nature of the environmental factors that influence this heterogeneity is also yet to be characterized. Nature Medicine, Nature Biotechnology and the Volkswagen Foundation organized a meeting focused on identifying the obstacles that need to be overcome to advance translational research in and tumor heterogeneity. Once these key questions were established, the attendees devised potential solutions. Their ideas are presented here.


    Publikations ID: 26248267
    Quelle: öffnen
     
    Drucken
     
    ccc_logo_en.gif
    ccc_logo_en.gif
    ccc_logo_en.gif

    Schnellinfo

     
    -- Initiative Krebsforschung / Krebsforschungslauf

    -- Cancer Care
    -- Kliniken und Partner
    -- CCC Cancer School
    -- Young CCC
    -- CCC Tumorboards
    -- CCC Forschungscluster
    -- CCC Units
    -- CCC Platforms
    -- SOPs / Leitlinien
    -- Kontakt
    Zuklappen
     
    Ausklappen
     
     

    Featured

     
     
     
     
     
     
     
     
     
     
     
     
     
    © MedUni Wien |
     Impressum | Nutzungsbedingungen | Kontakt